UCSF adopts Magseed as standard of care
Monday, 23 January, 2017
Endomag announced today that the University of California, San Francisco (UCSF) has become the first US site to adopt Magseed™ as its standard of care for localization of impalpable breast lesions. Magseed™ is a simpler, more effective alternative to traditional wire localization methods....
US Multi-Centre Trial Published at SABCS 2016
Thursday, 8 December, 2016
Endomag announced today that its Sentimag and Sienna system for sentinel lymph node detection in early stage breast cancer has been shown to be non-inferior to the current standard of care in US patients. The announcement follows completion of a multi-centre trial, which commenced in January...
IOP Commended Innovation Award win
Wednesday, 19 October, 2016
Endomag has received a Commended Innovation Award as part of the Institute of Physics (IOP) 2016 Business Innovation Awards. The IOP’s Commended Innovations are awarded to businesses for outstanding innovative applications of physics, which either push technological boundaries or provide bespoke...
Endomag and Devicor Medical Products Announce Distribution Agreement
Tuesday, 9 August, 2016
Endomag and Devicor Medical Products, a division of Leica Biosystems, are pleased to announce that Devicor Medical Products will be the exclusive distributor of Endomag's Sentimag, magnetic surgical guidance system, in the United States and Canada. This breakthrough technology provides a new...
FDA 510(k) Clearance Granted for Endomag’s Breast Tumor Localization System
Monday, 4 April, 2016
Endomag, the cancer healthcare company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Magseed® magnetic marker for use with Sentimag®.
Expanding its solutions for cancer clinicians and patients, Endomag’s Magseed® is designed to...